Análisis de la participación del virus de Epstein Barr en la patogénesis del linfoma difuso a grandes células B y su interacción con el microambiente tumoral

EBV-positive diffuse large B-cell lymphoma (DLBCL) of the elderly is a provisional entity included in the 2008 WHO classification of lymphoid tumors, that occurs in immunocompetent patients >50 years. It was proposed that it is related to the senescence of the immune system inherent to the aging...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autor principal: Cohen, Melina
Otros Autores: Álvarez, Élida
Formato: Tesis doctoral acceptedVersion
Lenguaje:Español
Publicado: Facultad de Farmacia y Bioquímica 2015
Materias:
Acceso en línea:http://repositoriouba.sisbi.uba.ar/gsdl/cgi-bin/library.cgi?a=d&c=posgraafa&cl=CL1&d=HWA_796
http://repositoriouba.sisbi.uba.ar/gsdl/collect/posgraafa/index/assoc/HWA_796.dir/796.PDF
Aporte de:
Descripción
Sumario:EBV-positive diffuse large B-cell lymphoma (DLBCL) of the elderly is a provisional entity included in the 2008 WHO classification of lymphoid tumors, that occurs in immunocompetent patients >50 years. It was proposed that it is related to the senescence of the immune system inherent to the aging process. Our aim was to study the role of EBV in the DLBCL pathogenesis in pediatric, young and older patients from our country and to characterize tumor microenvironment. One-hundred and two DLBCL cases were collected. EBERs in situ hybridization and immunohistochemistry for EBV antigens and lymphocytes populations were performed. EBV gene expression, cytokine and chemokine transcripts were analyzed using real-time PCR. EBV+ and ? cases from all age-groups were compared. EBV+ DLBCL frequency was similar in all age-groups; II and III viral latency pattern together with lytic expression were prevalent. PD-1 was predominant in all cases of DLBCL, while GrB was markedly increased in EBV+ DLBCL cases, in which a trend to lower event-free survival was noticed. Finally, EBV+ DLBCL may be an entity that is not only restricted to patients who are older than 50 years of age, in consequence the revision of age cutoff may be a current goal.